Market Research Logo

Epithelial Ovarian Cancer - Pipeline Review, H1 2015

Epithelial Ovarian Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Epithelial Ovarian Cancer - Pipeline Review, H1 2015’, provides an overview of the Epithelial Ovarian Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Epithelial Ovarian Cancer Overview
Therapeutics Development
Pipeline Products for Epithelial Ovarian Cancer - Overview
Pipeline Products for Epithelial Ovarian Cancer - Comparative Analysis
Epithelial Ovarian Cancer - Therapeutics under Development by Companies
Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
Epithelial Ovarian Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Epithelial Ovarian Cancer - Products under Development by Companies
Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes
Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development
AbbVie Inc.
Adaptimmune Limited
Amgen Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca PLC
Bayer AG
Bionomics Limited
BioNumerik Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Celldex Therapeutics, Inc.
Celon Pharma Sp. z o.o.
Celsion Corporation
Cerulean Pharma, Inc.
Clovis Oncology, Inc.
Eli Lilly and Company
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Glycotope GmbH
ImmunoGen, Inc.
Immunotope, Inc.
Johnson & Johnson
MabVax Therapeutics Holdings, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
NeoStem, Inc.
Novartis AG
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Oncobiologics, Inc.
Oncolytics Biotech Inc.
Onxeo SA
Otsuka Holdings Co., Ltd.
Oxford BioMedica plc
OXiGENE, Inc.
Pfizer Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
Prima BioMed Ltd.
PsiOxus Therapeutics, Ltd.
Sanofi
Sanofi Pasteur SA
Sotio a.s.
Synta Pharmaceuticals Corp.
Tesaro, Inc.
TetraLogic Pharmaceuticals
Therapeutic Proteins International, LLC
TRACON Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc.
Epithelial Ovarian Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abexinostat hydrochloride - Drug Profile
abiraterone acetate - Drug Profile
ABT-898 - Drug Profile
alisertib - Drug Profile
anetumab ravtansine - Drug Profile
Antisense Oligonucleotide for Ovarian and Colorectal Cancer - Drug Profile
AZD-1775 - Drug Profile
belinostat - Drug Profile
bevacizumab - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
birinapant - Drug Profile
BNC-105P - Drug Profile
cabozantinib s-malate - Drug Profile
Cancer Stem Cell Therapy - Drug Profile
catumaxomab - Drug Profile
CDX-1401 - Drug Profile
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile
cositecan - Drug Profile
CRLX-101 - Drug Profile
CVac - Drug Profile
DCVAC/OvCa - Drug Profile
DMUC-4064A - Drug Profile
EGEN-001 - Drug Profile
elesclomol - Drug Profile
enadenotucirev - Drug Profile
erismodegib - Drug Profile
fosbretabulin tromethamine - Drug Profile
ganetespib - Drug Profile
guadecitabine - Drug Profile
IMT-1012 - Drug Profile
LCL-161 - Drug Profile
lifastuzumab vedotin - Drug Profile
lurbinectedin - Drug Profile
LY-2606368 - Drug Profile
MesoCART - Drug Profile
mirvetuximab soravtansine - Drug Profile
motolimod - Drug Profile
NERX-313E - Drug Profile
NERX-505X - Drug Profile
nintedanib - Drug Profile
niraparib - Drug Profile
NSC-748933 - Drug Profile
OBI-822/821 - Drug Profile
OPB-111001 - Drug Profile
paclitaxel - Drug Profile
PankoMab-GEX - Drug Profile
pelareorep - Drug Profile
pembrolizumab - Drug Profile
PF-06647263 - Drug Profile
Procure - Drug Profile
Protein to Antagonize Frizzled Receptors for Epithelial Ovarian Cancer - Drug Profile
ralimetinib mesylate - Drug Profile
regorafenib - Drug Profile
rucaparib phosphate - Drug Profile
SAR-408701 - Drug Profile
sorafenib tosylate - Drug Profile
trabectedin - Drug Profile
TRC-105 - Drug Profile
trebananib - Drug Profile
TroVax - Drug Profile
Vaccine for Oncology - Drug Profile
Vaccine to Target Carcinoembryonic Antigen for Oncology - Drug Profile
Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile
Vaccine to Target IGFBP-2 for Epithelial Ovarian Cancer - Drug Profile
varlilumab - Drug Profile
vCP-2292 - Drug Profile
X-82 - Drug Profile
Epithelial Ovarian Cancer - Recent Pipeline Updates
Epithelial Ovarian Cancer - Dormant Projects
Epithelial Ovarian Cancer - Discontinued Products
Epithelial Ovarian Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Epithelial Ovarian Cancer, H1 2015
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2015
Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Adaptimmune Limited, H1 2015
Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by AstraZeneca PLC, H1 2015
Epithelial Ovarian Cancer - Pipeline by Bayer AG, H1 2015
Epithelial Ovarian Cancer - Pipeline by Bionomics Limited, H1 2015
Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Epithelial Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2015
Epithelial Ovarian Cancer - Pipeline by Celsion Corporation, H1 2015
Epithelial Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2015
Epithelial Ovarian Cancer - Pipeline by Exelixis, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Epithelial Ovarian Cancer - Pipeline by Genentech, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H1 2015
Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Immunotope, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H1 2015
Epithelial Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Merck & Co., Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by NeoStem, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Novartis AG, H1 2015
Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2015
Epithelial Ovarian Cancer - Pipeline by OBI Pharma, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Oncobiologics, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Onxeo SA, H1 2015
Epithelial Ovarian Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica plc, H1 2015
Epithelial Ovarian Cancer - Pipeline by OXiGENE, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Pfizer Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H1 2015
Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H1 2015
Epithelial Ovarian Cancer - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015
Epithelial Ovarian Cancer - Pipeline by Sanofi, H1 2015
Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H1 2015
Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H1 2015
Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Epithelial Ovarian Cancer - Pipeline by Tesaro, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2015
Epithelial Ovarian Cancer - Pipeline by Therapeutic Proteins International, LLC, H1 2015
Epithelial Ovarian Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015
Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Epithelial Ovarian Cancer - Dormant Projects, H1 2015
Epithelial Ovarian Cancer - Dormant Projects (Contd..1), H1 2015
Epithelial Ovarian Cancer - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Epithelial Ovarian Cancer, H1 2015
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report